Kezar Life Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Kezar Life Sciences wird ein Gewinn- und Umsatzwachstum von 7.4% bzw. 48% pro Jahr prognostiziert, während der Gewinn pro Aktie um 12.8% pro Jahr wachsen soll.

Wichtige Informationen

7.4%

Wachstumsrate der Gewinne

12.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	48.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Dec 08

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Oct 03

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Aug 26

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Apr 05

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Mar 01

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Jan 25

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Dec 21

Kezar Life Sciences selected for the Nasdaq Biotechnology Index

Dec 14

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:KZR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-64	N/A	-26	4
12/31/2025	3	-69	N/A	-38	6
12/31/2024	N/A	-83	N/A	-69	5
9/30/2024	N/A	-96	-76	-76	N/A
6/30/2024	7	-99	-79	-79	N/A
3/31/2024	7	-101	-85	-84	N/A
12/31/2023	7	-102	-83	-82	N/A
9/30/2023	7	-88	-81	-79	N/A
6/30/2023	N/A	-83	-77	-75	N/A
3/31/2023	N/A	-74	-68	-66	N/A
12/31/2022	N/A	-68	-60	-59	N/A
9/30/2022	N/A	-64	-56	-54	N/A
6/30/2022	N/A	-61	-49	-48	N/A
3/31/2022	N/A	-58	-48	-47	N/A
12/31/2021	N/A	-55	-43	-42	N/A
9/30/2021	N/A	-51	-41	-41	N/A
6/30/2021	N/A	-48	-40	-40	N/A
3/31/2021	N/A	-45	-37	-37	N/A
12/31/2020	N/A	-42	-37	-37	N/A
9/30/2020	N/A	-40	-35	-35	N/A
6/30/2020	N/A	-38	-34	-34	N/A
3/31/2020	N/A	-37	-32	-31	N/A
12/31/2019	N/A	-35	-30	-30	N/A
9/30/2019	N/A	-31	-29	-28	N/A
6/30/2019	N/A	-28	-25	-24	N/A
3/31/2019	N/A	-26	-25	-24	N/A
12/31/2018	N/A	-23	-22	-21	N/A
9/30/2018	N/A	-20	-18	-17	N/A
6/30/2018	N/A	-16	N/A	-15	N/A
3/31/2018	N/A	-11	N/A	-10	N/A
12/31/2017	N/A	-9	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KZR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KZR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KZR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KZRDie Einnahmen des Unternehmens (48% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: KZRDie Einnahmen des Unternehmens (48% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KZR in 3 Jahren voraussichtlich hoch sein wird

Kezar Life Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 23%

Price target decreased by 8.0% to US$15.33

Price target decreased by 7.7% to US$16.00

Price target decreased by 9.1% to US$16.67

Price target decreased to US$17.33

Price target increased to US$19.67

Recent updates

Kezar Life Sciences Regain Compliance with Nasdaq Listing Rule 5550(a)(2)

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement Required to Maintain Continued Listing on the Nasdaq Capital Market

Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. (NasdaqCM:KZR) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

Concentra Biosciences, LLC submitted a non-binding proposal to acquire Kezar Life Sciences, Inc. (NasdaqCM:KZR) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $80.3 million.

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Life Sciences, Inc. Announces Cessation of Enrollment and Dosing in the Phase 2B Palizade Trial of Zetomipzomib in Active Lupus Nephritis Patients

Kezar Life Sciences, Inc. Provides Business Update

Kezar Life Sciences, Inc. to Transfer Its Listing to the Nasdaq Capital Market

Kezar Life Sciences, Inc., Annual General Meeting, Jun 18, 2024

Consensus EPS estimates fall by 23%

Kezar Life Sciences Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Kezar Life Sciences, Inc. Announces CEO Changes

New minor risk - Market cap size

New minor risk - Share price stability

Price target decreased by 8.0% to US$15.33

Price target decreased by 7.7% to US$16.00

Price target decreased by 9.1% to US$16.67

Price target decreased to US$17.33

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Kezar Life Sciences, Inc. Presents Positive Complete Results from the Mission Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis At the American College of Rheumatology Convergence 2022

Kezar Life Sciences, Inc. Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual Meeting

Kezar Life Sciences, Inc. Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

Kezar Life Sciences appoints Nick Mordwinkin as chief business officer

Price target increased to US$19.67

Kezar Life Sciences, Inc. Announces Positive Topline Results from the Mission Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

Kezar Life Sciences, Inc. Announces Executive Changes

Price target decreased to US$20.67

Kezar Life Sciences, Inc. Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis

Price target increased to US$22.67

Independent Director recently bought US$1.3m worth of stock

Independent Director exercised options and sold US$53k worth of stock

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Price target increased to US$20.67

Price target increased to US$17.67

Independent Director exercised options to buy US$238k worth of stock.

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

Kezar Life Sciences, Inc. Presents Results of the Completed MISSION Phase 1B Study of KZR-616 at EULAR 2021

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

New 90-day high: US$6.99

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Kezar Life Sciences selected for the Nasdaq Biotechnology Index

New 90-day high: US$6.00

Kezar Life Sciences, Inc. Provides Update on KZR-616: Selective Immunoproteasome Inhibitor and KZR-261: Protein Secretion Program

New 90-day high: US$5.20

Kezar Life Sciences, Inc. to Report Q2, 2020 Results on Aug 05, 2020

New 90-day low - US$4.36

Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from Russell 3000 Growth Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken